Sessions:
AI • Radiopharmaceuticals • Next-Gen Targeted and Immune Therapies
Precision Oncology through Targeted Protein Degradation Mechanisms
Duane Roth Achievement Award
Featured Presentations
Session Chair
Eric Bennett, PhD, Professor, Department of Cell and Developmental Biology, UC San Diego
Powering Early-Stage Drug Discovery with AI/ML & Community
Vanessa Braunstein, Senior Director, TuneLab AI Drug Discovery Platform, Lilly
Kathleen Lin, Senior Director, Site Head, Lilly Gateway Labs San Diego
AI/ML for Forward/Reverse Translation
Jadwiga Bienkowska, PhD, Senior Director, Head of Computational Biology Oncology R&D, Pfizer
Darlifarnib- bench to bedside development of a next-gen FTI in combination with cabozantinib in RCC
Francis Burrows, PhD, Chief Scientific Officer, Kura Oncology
Expanding the scope of molecular glues into new targets and indications
Phil Chamberlain, DPhil, Co-Founder, President, and CEO, Neomorph
ZBTB11 Depletion Targets Metabolic Vulnerabilities in K-Ras Inhibitor Resistant PDAC
Fleur Ferguson, PhD, Assistant Professor, Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego
Omnimodal AI for Precision Oncology: Integrating Data to Drive Discovery
Nathan Fowler, MD, Chief Medical Officer, BostonGene Corporation
AI Enables Rapid Identification of Targeted Cancer Therapy
Rick Fultz, Chief Executive Officer, Board Member, Acurion, Inc.
DR5 Agonist Clinical Data in Chondrosarcoma, Colorectal Cancer and Ewings Sarcoma
Josep Garcia, PhD, Executive Vice President, Chief Clinical Development Officer, Inhibrx
Katelyn Willis, PhD, Director, Biotherapeutics, Inhibrx
HER3-Targeted Antibody-Drug Conjugates for IO Combination Therapy
J. Silvio Gutkind, PhD, Chair, Department of Pharmacology, Moores Cancer Center, UC San Diego
Session Chair
Jake Haling, PhD, Head of Oncology Drug Discovery, San Diego, Novartis Institutes for Biomedical Research
Session Chair
Analeah Heidt, PhD, Chief Scientific Officer, Enlaza Therapeutics
Digital Tumors for Precision Oncology
Trey Ideker, PhD, Professor, Department of Medicine, Adjunct Professor, Departments of Bioengineering and Computer Science, UC San Diego
AI-Guided Proteogenomics for Precision Oncology: Decoding Therapeutic Response in AML
Pilgrim Jackson, PhD, Chief Executive Officer, Yatiri Bio
Session Chair
Shweta Joshi, PhD, Assistant Professor, Department of Pediatrics, Moores Cancer Center, UC San Diego
Targeted alpha therapy with 212Pb, a short-lived isotope with long-lived benefit
Gary Li, PhD, Chief Strategy Officer, AdvanCell
Advancing Novel Precision Oncology Therapeutics with Monovalent Targeted Protein Degraders
Michael Martin, PhD, Chief Executive Officer, Plexium
From Models to Medicines: Delivering on the Promise of AI-Driven Drug Discovery
Tom Miller, PhD, Co-Founder and CEO, Iambic Therapeutics
AI-Based Automated Planning for Breast Radiotherapy: A Precision Individualized Approach
Lance Moore, MS, Quality, Innovation, Value, and Efficiency in Radiotherapy (QUIVER) Center, Radiation Medicine and Applied Sciences, UC San Diego
Integrating radiopharmaceuticals in combined modality treatments for cancer
Zachary Morris, MD, PhD, Associate Professor and Chair, Department of Human Oncology, University of Wisconsin-Madison
Welcome Remarks
Arno J. Mundt, MD, FACRO, FASTRO, Professor and Founding Chair, Radiation Medicine and Applied Sciences, Executive Governing Committee, Moores Cancer Center, UC San Diego
Session Chair
Sandip Patel, MD, Division of Hematology and Oncology, Department of Medicine, Moores Cancer Center, UC San Diego
Session Chair
Paul Rejto, PhD, Vice President, Discovery Technologies, Pfizer
Expanding Access to Radioligand Therapies: Reaching Every Patient, Everywhere
Brent Rose, MD, Associate Professor, Director, Division of Radiation Oncology, Co-Director, Center for Health Equity, Education and Research, Radiation Medicine and Applied Sciences, UC San Diego
The landscape of opportunities for combining theranostics and radiotherapy in prostate cancer
Tyler Seibert, MD, PhD, Center for Precision Radiation Medicine, Radiation Medicine and Applied Sciences, UC San Diego
Session Chair & Closing Remarks
Andrew Sharabi, MD, PhD, Professor & Jacobs Chancellor's Endowed Chair in Radiation Medicine and Applied Sciences, Director, Center for Precision Radiation Medicine, Moores Cancer Cancer, UC San Diego
The Proteostasis Network is a Therapeutic Target in Acute Myeloid Leukemia
Robert Signer, PhD, Deputy Director, Stem Cell Discovery Center, Associate Professor of Medicine, Division of Regenerative Medicine, Sanford Stem Cell Institute, UC San Diego
Pioneering αRPT: Opportunities for Collaboration
Eileen Sneeden, PhD, Senior Director, Radiation Biophysics & Nuclear Oncology Liaison, RayzeBio, a Bristol Myers Squibb Company
Duane Roth Achievement Award
Evolution of Personalization and Precision Medicine in Radiation Oncology
Catheryn Yashar, MD, FACRO, FABS, FACR, FASTRO, Professor & Vice Chair of Clinical Affairs, Division of Radiation Oncology, Radiation Medicine and Applied Sciences, Chief Medical Officer, Health System, UC San Diego
Targeting Tumor Microenvironment with Radioligands
Frederic Zecri, PhD, Chief Scientific Officer, Mariana Therapeutics, a Novartis company
Archived Agendas
The success of the Symposium is made possible by our dynamic sessions featuring distinguished leaders from industry and academia.
View Past Agendas: 2024 Agenda (PDF) | 2023 Agenda (PDF)
2022 Agenda (PDF) | 2021 Agenda (PDF) |
2020 Agenda (PDF) | 2019 Agenda (PDF)